Novartis loses $940M arbitration case against Mitsubishi Chemical over Gilenya royalties

Novartis has made more than $30 billion from sales of its multiple sclerosis therapy Gilenya. But lately the drug’s decline has brought headaches for the Swiss pharma giant.

A series of patent defeats has led Novartis to a last ditch appeal with the U.S. Supreme Court. Now, the company has been told to fork over $940 million in royalties to Mitsubishi Chemical Group.